Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor

An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmacology Vol. 103; no. 3; pp. 176 - 187
Main Authors Wang, Xushan, Hembre, Erik J., Goldsmith, Paul J., Beck, James P., Svensson, Kjell A., Willard, Francis S., Bruns, Robert F.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.03.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC50 than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein–coupled receptors.
AbstractList An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. SIGNIFICANCE STATEMENT: Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein-coupled receptors.
An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC50 than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. SIGNIFICANCE STATEMENT: Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein-coupled receptors.An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC50 than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. SIGNIFICANCE STATEMENT: Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein-coupled receptors.
An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC50 than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein–coupled receptors.
Author Willard, Francis S.
Bruns, Robert F.
Hembre, Erik J.
Beck, James P.
Svensson, Kjell A.
Goldsmith, Paul J.
Wang, Xushan
Author_xml – sequence: 1
  givenname: Xushan
  surname: Wang
  fullname: Wang, Xushan
– sequence: 2
  givenname: Erik J.
  surname: Hembre
  fullname: Hembre, Erik J.
– sequence: 3
  givenname: Paul J.
  surname: Goldsmith
  fullname: Goldsmith, Paul J.
– sequence: 4
  givenname: James P.
  surname: Beck
  fullname: Beck, James P.
– sequence: 5
  givenname: Kjell A.
  surname: Svensson
  fullname: Svensson, Kjell A.
– sequence: 6
  givenname: Francis S.
  orcidid: 0000-0002-4260-2451
  surname: Willard
  fullname: Willard, Francis S.
  email: willardfs@lilly.com
– sequence: 7
  givenname: Robert F.
  orcidid: 0000-0001-7142-9881
  surname: Bruns
  fullname: Bruns, Robert F.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36804203$$D View this record in MEDLINE/PubMed
BookMark eNp9kE1r3DAQhkVJaDZpf0Gh6NiLtzOSZUuHHsL2M6QU2gRyE4o8ZlVsy5XkQP59XTZ76SGnmcP7vMw85-xkihMx9gZhiyjq92Mc5r1L4xaF2AJAA-oF26ASWAEinrANgGgqbdTdGTvP-TcA1krDS3YmGw21ALlhV9-XsriB72KcKbkSHkJ55LHnN_tExC-HIeZCKXj-KxTKPE687Il_jLMbw7QuyH-Sp7nE9Iqd9m7I9PppXrDbz59udl-r6x9fvu0urysv0ajKKQXGCI1QI3aNkE4okqZtjalb2Uitu_U6aIR2XvXmXna9g7buiRT02qC8YO8OvXOKfxbKxY4hexoGN1FcshVtq00rjBJr9O1TdLkfqbNzCqNLj_b4_xowh4BPMedEvfWhrBbiVJILg0Ww_1zbo2u7urYH1ysr_2OP9c9THw4UrYoeAiWbfaDJUxcS-WK7GJ7l_wK61pdi
CitedBy_id crossref_primary_10_1016_j_neuroscience_2024_10_004
crossref_primary_10_3390_ijms241612848
crossref_primary_10_1016_j_rechem_2024_101363
crossref_primary_10_1093_nar_gkad279
Cites_doi 10.3389/fnint.2014.00056
10.1016/j.drudis.2020.12.001
10.1016/j.biopsych.2015.12.028
10.1016/S0026-895X(25)13145-3
10.1002/mds.28879
10.1038/nature12735
10.1096/fasebj.2021.35.S1.02361
10.1038/nature09648
10.1021/acs.jmedchem.1c02169
10.1523/JNEUROSCI.17-21-08580.1997
10.1124/mol.118.112649
10.1021/acs.jmedchem.9b01234
10.2174/1568026619666190712210903
10.1124/mol.118.113175
10.1016/j.vascn.2014.01.002
10.1016/S0022-2836(65)80285-6
10.1016/bs.apha.2019.06.001
10.1016/j.cell.2021.01.028
10.1038/nrd3954
10.1146/annurev.pharmtox.47.120505.105159
10.1038/s41467-022-30929-w
10.1038/s41586-018-0259-z
10.1016/j.neuropharm.2017.10.032
10.1021/acschembio.2c00048
10.1124/jpet.116.236372
10.1016/S0026-895X(25)14327-7
10.1124/pr.110.002642
10.1016/S0026-895X(25)09591-4
10.1021/acs.jmedchem.5b01105
10.1038/s41586-021-03897-2
10.1124/jpet.115.224071
10.1124/pr.54.2.323
10.1177/1087057109357789
10.1038/287651a0
10.1016/j.tips.2016.06.001
10.1073/pnas.95.7.4040
10.1126/science.1215904
10.1038/nrd.2016.230
10.1038/s41422-021-00482-0
ContentType Journal Article
Copyright 2023 American Society for Pharmacology and Experimental Therapeutics
Copyright © 2023 by The Author(s).
Copyright_xml – notice: 2023 American Society for Pharmacology and Experimental Therapeutics
– notice: Copyright © 2023 by The Author(s).
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1124/molpharm.122.000605
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-0111
EndPage 187
ExternalDocumentID 36804203
10_1124_molpharm_122_000605
S0026895X24012732
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
0R~
123
18M
2WC
34G
39C
4.4
53G
5RE
5VS
AAXUO
ABCQX
ABJNI
ABSQV
ACGFO
ACGFS
ADBBV
ADCOW
AENEX
AERNN
AFFNX
AFOSN
ALMA_UNASSIGNED_HOLDINGS
AYCSE
BAWUL
BTFSW
CS3
DIK
E3Z
EBS
EJD
F5P
F9R
FDB
GX1
H13
HZ~
IH2
INIJC
K-O
KQ8
L7B
LSO
M41
MVM
N9A
O9-
OK1
P2P
R.V
R0Z
RHI
ROL
RPT
TR2
UQL
W8F
WOQ
X7M
XOL
YBU
YHG
ZGI
ZXP
AALRI
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3195-a550992810411d623a25e3977994736388d6800628ac5f9b3dfa074fee50f8913
ISSN 0026-895X
1521-0111
IngestDate Fri Jul 11 08:28:41 EDT 2025
Thu Apr 03 07:05:13 EDT 2025
Thu Apr 24 23:02:29 EDT 2025
Tue Jul 01 05:29:34 EDT 2025
Sun Apr 06 06:54:50 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords GPCR
ICL2
NAM
CRC
PAM
ECL
Language English
License Copyright © 2023 by The Author(s).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3195-a550992810411d623a25e3977994736388d6800628ac5f9b3dfa074fee50f8913
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4260-2451
0000-0001-7142-9881
OpenAccessLink https://molpharm.aspetjournals.org/content/molpharm/early/2022/12/09/molpharm.122.000605.full.pdf
PMID 36804203
PQID 2778972952
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_2778972952
pubmed_primary_36804203
crossref_citationtrail_10_1124_molpharm_122_000605
crossref_primary_10_1124_molpharm_122_000605
elsevier_sciencedirect_doi_10_1124_molpharm_122_000605
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2023
2023-03-00
20230301
PublicationDateYYYYMMDD 2023-03-01
PublicationDate_xml – month: 03
  year: 2023
  text: March 2023
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmacology
PublicationTitleAlternate Mol Pharmacol
PublicationYear 2023
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Kruse, Ring, Manglik, Hu, Hu, Eitel, Hübner, Pardon, Valant, Sexton (bib22) 2013; 504
Nemeth, Steffey, Hammerland, Hung, Van Wagenen, DelMar, Balandrin (bib30) 1998; 95
Bruns, Mitchell, Wafford, Harper, Shanks, Carter, O’Neill, Murray, Eastwood, Schaus (bib7) 2018; 128
Wang, Yu, Xiao, Lu, Zhang (bib40) 2021; 26
Biglan, Munsie, Svensson, Ardayfio, Pugh, Sims, Brys (bib5) 2022; 37
Kenakin, Christopoulos (bib20) 2013; 12
Santos, Ursu, Gaulton, Bento, Donadi, Bologa, Karlsson, Al-Lazikani, Hersey, Oprea (bib32) 2017; 16
Luderman, Free, Koenigsberg, Aubé, Frankowski, Neve, Sibley (bib24) 2021; 35
Christopoulos, Kenakin (bib8) 2002; 54
Ikemoto, Glazier, Murphy, McBride (bib18) 1997; 17
Hany, Leyris, Bret, Mallié, Sar, Thouaye, Hamze, Provot, Sokoloff, Valmier (bib16) 2022; 17
Thal, Glukhova, Sexton, Christopoulos (bib38) 2018; 559
Hao, Beck, Schaus, Krushinski, Chen, Beadle, Vidal, Reinhard, Dressman, Massey (bib17) 2019; 62
Ehlert, Griffin (bib10) 2014; 69
Beadle CD, Coates DA, Hao J, Krushinski JH, Reinhard MR, Schaus JM, Wolfangel CD (2014) 3,4-dihydroisoquinolin-2(1H)-yl compounds. Patent WO 2014/193781 A1, pp 1-90. 2014 Apr 12.
Naidu, Patel, McAuliffe, Ding, Cianci, Simmermacher, Jenkins, Parker, Sivaprakasam, Khan (bib28) 2022; 65
Nakamura, Sato, Kitsukawa, Momiyama, Yamamori, Sasaoka (bib29) 2014; 8
Svensson, Heinz, Schaus, Beck, Hao, Krushinski, Reinhard, Cohen, Hellman, Getman (bib36) 2017; 360
Xiao, Yan, Gou, Zhong, Kong, Wu, Wen, Yuan, Cao, Qu (bib41) 2021; 184
Ehlert (bib11) 1988; 33
Alexander, Christopoulos, Davenport, Kelly, Mathie, Peters, Veale, Armstrong, Faccenda, Harding (bib1) 2021; 178
Wang, Heinz, Qian, Carter, Gadski, Beavers, Little, Yang, Beck, Hao (bib39) 2018; 94
Lewis, Hunihan, Watson, Gentles, Hu, Huang, Bronson, Macor, Beno, Ferrante (bib23) 2015; 354
Rasmussen, Choi, Fung, Pardon, Casarosa, Chae, Devree, Rosenbaum, Thian, Kobilka (bib31) 2011; 469
Hanson, Roth, Jo, Griffith, Scott, Reinhart, Desale, Clemons, Cahalan, Schuerer (bib15) 2012; 335
Teng, Chen, Nie, Xiao, Yu, Shao, Zheng (bib37) 2022; 13
Irwin, Duan, Torosyan, Doak, Ziebart, Sterling, Tumanian, Shoichet (bib19) 2015; 58
Beaulieu, Gainetdinov (bib4) 2011; 63
Draper-Joyce, Bhola, Wang, Bhattarai, Nguyen, Cowie-Kent, O’Sullivan, Chia, Venugopal, Valant (bib9) 2021; 597
Luderman, Conroy, Free, Southall, Ferrer, Sanchez-Soto, Moritz, Willette, Fyfe, Jain (bib25) 2018; 94
Shiraki, Tobe, Kawakami, Moritomo, Ohmiya (bib33) 2015
Arnsten, Girgis, Gray, Mailman (bib2) 2017; 81
Svensson, Hao, Bruns (bib35) 2019; 86
Monod, Wyman, Changeux (bib27) 1965; 12
Zhuang, Krumm, Zhang, Zhou, Wang, Huang, Liu, Cheng, Jiang, Jiang (bib42) 2021; 31
Felsing, Jain, Allen (bib13) 2019; 19
Kenakin (bib21) 2010; 15
Bruns, Fergus (bib6) 1990; 38
May, Leach, Sexton, Christopoulos (bib26) 2007; 47
Stockton, Birdsall, Burgen, Hulme (bib34) 1983; 23
Gavish, Snyder (bib14) 1980; 287
Ehlert (bib12) 2016; 37
Teng (10.1124/molpharm.122.000605_bib37) 2022; 13
Felsing (10.1124/molpharm.122.000605_bib13) 2019; 19
Kruse (10.1124/molpharm.122.000605_bib22) 2013; 504
Ehlert (10.1124/molpharm.122.000605_bib12) 2016; 37
10.1124/molpharm.122.000605_bib3
Gavish (10.1124/molpharm.122.000605_bib14) 1980; 287
Ehlert (10.1124/molpharm.122.000605_bib10) 2014; 69
Luderman (10.1124/molpharm.122.000605_bib24) 2021; 35
Svensson (10.1124/molpharm.122.000605_bib36) 2017; 360
Alexander (10.1124/molpharm.122.000605_bib1) 2021; 178
Nemeth (10.1124/molpharm.122.000605_bib30) 1998; 95
Wang (10.1124/molpharm.122.000605_bib39) 2018; 94
Beaulieu (10.1124/molpharm.122.000605_bib4) 2011; 63
Ehlert (10.1124/molpharm.122.000605_bib11) 1988; 33
Luderman (10.1124/molpharm.122.000605_bib25) 2018; 94
Rasmussen (10.1124/molpharm.122.000605_bib31) 2011; 469
Svensson (10.1124/molpharm.122.000605_bib35) 2019; 86
Thal (10.1124/molpharm.122.000605_bib38) 2018; 559
Irwin (10.1124/molpharm.122.000605_bib19) 2015; 58
Hao (10.1124/molpharm.122.000605_bib17) 2019; 62
Kenakin (10.1124/molpharm.122.000605_bib21) 2010; 15
Stockton (10.1124/molpharm.122.000605_bib34) 1983; 23
Kenakin (10.1124/molpharm.122.000605_bib20) 2013; 12
Lewis (10.1124/molpharm.122.000605_bib23) 2015; 354
Ikemoto (10.1124/molpharm.122.000605_bib18) 1997; 17
Bruns (10.1124/molpharm.122.000605_bib7) 2018; 128
Wang (10.1124/molpharm.122.000605_bib40) 2021; 26
Zhuang (10.1124/molpharm.122.000605_bib42) 2021; 31
May (10.1124/molpharm.122.000605_bib26) 2007; 47
Santos (10.1124/molpharm.122.000605_bib32) 2017; 16
Arnsten (10.1124/molpharm.122.000605_bib2) 2017; 81
Christopoulos (10.1124/molpharm.122.000605_bib8) 2002; 54
Hanson (10.1124/molpharm.122.000605_bib15) 2012; 335
Naidu (10.1124/molpharm.122.000605_bib28) 2022; 65
Xiao (10.1124/molpharm.122.000605_bib41) 2021; 184
Monod (10.1124/molpharm.122.000605_bib27) 1965; 12
Biglan (10.1124/molpharm.122.000605_bib5) 2022; 37
Bruns (10.1124/molpharm.122.000605_bib6) 1990; 38
Draper-Joyce (10.1124/molpharm.122.000605_bib9) 2021; 597
Shiraki (10.1124/molpharm.122.000605_bib33) 2015
Hany (10.1124/molpharm.122.000605_bib16) 2022; 17
Nakamura (10.1124/molpharm.122.000605_bib29) 2014; 8
References_xml – volume: 33
  start-page: 187
  year: 1988
  end-page: 194
  ident: bib11
  article-title: Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods
  publication-title: Mol Pharmacol
– volume: 94
  start-page: 1197
  year: 2018
  end-page: 1209
  ident: bib25
  article-title: Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites
  publication-title: Mol Pharmacol
– volume: 26
  start-page: 690
  year: 2021
  end-page: 703
  ident: bib40
  article-title: Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery
  publication-title: Drug Discov Today
– start-page: A1
  year: 2015
  ident: bib33
  article-title: Heterocyclic acetamide compound
  publication-title: Patent
– volume: 38
  start-page: 939
  year: 1990
  end-page: 949
  ident: bib6
  article-title: Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes
  publication-title: Mol Pharmacol
– volume: 178
  start-page: S27
  year: 2021
  end-page: S156
  ident: bib1
  article-title: THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors
  publication-title: Br J Pharmacol
– volume: 81
  start-page: 67
  year: 2017
  end-page: 77
  ident: bib2
  article-title: Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia
  publication-title: Biol Psychiatry
– volume: 86
  start-page: 273
  year: 2019
  end-page: 305
  ident: bib35
  article-title: Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders
  publication-title: Adv Pharmacol
– volume: 559
  start-page: 45
  year: 2018
  end-page: 53
  ident: bib38
  article-title: Structural insights into G-protein-coupled receptor allostery
  publication-title: Nature
– volume: 597
  start-page: 571
  year: 2021
  end-page: 576
  ident: bib9
  article-title: Positive allosteric mechanisms of adenosine A
  publication-title: Nature
– volume: 69
  start-page: 253
  year: 2014
  end-page: 279
  ident: bib10
  article-title: Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias
  publication-title: J Pharmacol Toxicol Methods
– volume: 16
  start-page: 19
  year: 2017
  end-page: 34
  ident: bib32
  article-title: A comprehensive map of molecular drug targets
  publication-title: Nat Rev Drug Discov
– volume: 62
  start-page: 8711
  year: 2019
  end-page: 8732
  ident: bib17
  article-title: Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1
  publication-title: J Med Chem
– volume: 23
  start-page: 551
  year: 1983
  end-page: 557
  ident: bib34
  article-title: Modification of the binding properties of muscarinic receptors by gallamine
  publication-title: Mol Pharmacol
– volume: 37
  start-page: 620
  year: 2016
  end-page: 623
  ident: bib12
  article-title: Cooperativity Has Empirical and Ultimate Levels of Explanation
  publication-title: Trends Pharmacol Sci
– volume: 17
  start-page: 8580
  year: 1997
  end-page: 8587
  ident: bib18
  article-title: Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward
  publication-title: J Neurosci
– volume: 63
  start-page: 182
  year: 2011
  end-page: 217
  ident: bib4
  article-title: The physiology, signaling, and pharmacology of dopamine receptors
  publication-title: Pharmacol Rev
– volume: 12
  start-page: 88
  year: 1965
  end-page: 118
  ident: bib27
  article-title: On the nature of allosteric transitions: a plausible model
  publication-title: J Mol Biol
– volume: 12
  start-page: 205
  year: 2013
  end-page: 216
  ident: bib20
  article-title: Signalling bias in new drug discovery: detection, quantification and therapeutic impact
  publication-title: Nat Rev Drug Discov
– volume: 31
  start-page: 593
  year: 2021
  end-page: 596
  ident: bib42
  article-title: Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor
  publication-title: Cell Res
– reference: Beadle CD, Coates DA, Hao J, Krushinski JH, Reinhard MR, Schaus JM, Wolfangel CD (2014) 3,4-dihydroisoquinolin-2(1H)-yl compounds. Patent WO 2014/193781 A1, pp 1-90. 2014 Apr 12.
– volume: 15
  start-page: 119
  year: 2010
  end-page: 130
  ident: bib21
  article-title: Ligand detection in the allosteric world
  publication-title: J Biomol Screen
– volume: 354
  start-page: 340
  year: 2015
  end-page: 349
  ident: bib23
  article-title: Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity
  publication-title: J Pharmacol Exp Ther
– volume: 19
  start-page: 1365
  year: 2019
  end-page: 1380
  ident: bib13
  article-title: Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics
  publication-title: Curr Top Med Chem
– volume: 54
  start-page: 323
  year: 2002
  end-page: 374
  ident: bib8
  article-title: G protein-coupled receptor allosterism and complexing
  publication-title: Pharmacol Rev
– volume: 469
  start-page: 175
  year: 2011
  end-page: 180
  ident: bib31
  article-title: Structure of a nanobody-stabilized active state of the β(2) adrenoceptor
  publication-title: Nature
– volume: 8
  start-page: 56
  year: 2014
  ident: bib29
  article-title: Distinct motor impairments of dopamine D1 and D2 receptor knockout mice revealed by three types of motor behavior
  publication-title: Front Integr Nuerosci
– volume: 335
  start-page: 851
  year: 2012
  end-page: 855
  ident: bib15
  article-title: Crystal structure of a lipid G protein-coupled receptor
  publication-title: Science
– volume: 504
  start-page: 101
  year: 2013
  end-page: 106
  ident: bib22
  article-title: Activation and allosteric modulation of a muscarinic acetylcholine receptor
  publication-title: Nature
– volume: 94
  start-page: 1232
  year: 2018
  end-page: 1245
  ident: bib39
  article-title: Intracellular binding site for a positive allosteric modulator of the dopamine D1 receptor
  publication-title: Mol Pharmacol
– volume: 37
  start-page: 513
  year: 2022
  end-page: 524
  ident: bib5
  article-title: Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial
  publication-title: Mov Disord
– volume: 287
  start-page: 651
  year: 1980
  end-page: 652
  ident: bib14
  article-title: Benzodiazepine recognition sites on GABA receptors
  publication-title: Nature
– volume: 58
  start-page: 7076
  year: 2015
  end-page: 7087
  ident: bib19
  article-title: An Aggregation Advisor for Ligand Discovery
  publication-title: J Med Chem
– volume: 47
  start-page: 1
  year: 2007
  end-page: 51
  ident: bib26
  article-title: Allosteric modulation of G protein-coupled receptors
  publication-title: Annu Rev Pharmacol Toxicol
– volume: 128
  start-page: 351
  year: 2018
  end-page: 365
  ident: bib7
  article-title: Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders
  publication-title: Neuropharmacology
– volume: 17
  start-page: 709
  year: 2022
  end-page: 722
  ident: bib16
  article-title: High-Throughput Screening for Extracellular Inhibitors of the FLT3 Receptor Tyrosine Kinase Reveals Chemically Diverse and Druggable Negative Allosteric Modulators
  publication-title: ACS Chem Biol
– volume: 35
  start-page: 2361
  year: 2021
  ident: bib24
  article-title: Characterization of a D1 Dopamine Receptor Positive Allosteric Modulator with a Novel Binding Site (Abstract)
  publication-title: FASEB J
– volume: 13
  start-page: 3186
  year: 2022
  ident: bib37
  article-title: Ligand recognition and biased agonism of the D1 dopamine receptor
  publication-title: Nat Commun
– volume: 360
  start-page: 117
  year: 2017
  end-page: 128
  ident: bib36
  article-title: An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis
  publication-title: J Pharmacol Exp Ther
– volume: 95
  start-page: 4040
  year: 1998
  end-page: 4045
  ident: bib30
  article-title: Calcimimetics with potent and selective activity on the parathyroid calcium receptor
  publication-title: Proc Natl Acad Sci USA
– volume: 65
  start-page: 4949
  year: 2022
  end-page: 4971
  ident: bib28
  article-title: Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs
  publication-title: J Med Chem
– volume: 184
  start-page: 943
  year: 2021
  end-page: 956.e18
  ident: bib41
  article-title: Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes
  publication-title: Cell
– volume: 8
  start-page: 56
  year: 2014
  ident: 10.1124/molpharm.122.000605_bib29
  article-title: Distinct motor impairments of dopamine D1 and D2 receptor knockout mice revealed by three types of motor behavior
  publication-title: Front Integr Nuerosci
  doi: 10.3389/fnint.2014.00056
– volume: 26
  start-page: 690
  year: 2021
  ident: 10.1124/molpharm.122.000605_bib40
  article-title: Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2020.12.001
– volume: 81
  start-page: 67
  year: 2017
  ident: 10.1124/molpharm.122.000605_bib2
  article-title: Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2015.12.028
– volume: 33
  start-page: 187
  year: 1988
  ident: 10.1124/molpharm.122.000605_bib11
  article-title: Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods
  publication-title: Mol Pharmacol
  doi: 10.1016/S0026-895X(25)13145-3
– volume: 37
  start-page: 513
  year: 2022
  ident: 10.1124/molpharm.122.000605_bib5
  article-title: Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial
  publication-title: Mov Disord
  doi: 10.1002/mds.28879
– volume: 504
  start-page: 101
  year: 2013
  ident: 10.1124/molpharm.122.000605_bib22
  article-title: Activation and allosteric modulation of a muscarinic acetylcholine receptor
  publication-title: Nature
  doi: 10.1038/nature12735
– volume: 35
  start-page: 2361
  issue: S1
  year: 2021
  ident: 10.1124/molpharm.122.000605_bib24
  article-title: Characterization of a D1 Dopamine Receptor Positive Allosteric Modulator with a Novel Binding Site (Abstract)
  publication-title: FASEB J
  doi: 10.1096/fasebj.2021.35.S1.02361
– volume: 469
  start-page: 175
  year: 2011
  ident: 10.1124/molpharm.122.000605_bib31
  article-title: Structure of a nanobody-stabilized active state of the β(2) adrenoceptor
  publication-title: Nature
  doi: 10.1038/nature09648
– volume: 65
  start-page: 4949
  year: 2022
  ident: 10.1124/molpharm.122.000605_bib28
  article-title: Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.1c02169
– start-page: A1
  issue: Number: US20150045402
  year: 2015
  ident: 10.1124/molpharm.122.000605_bib33
  article-title: Heterocyclic acetamide compound
  publication-title: Patent
– volume: 17
  start-page: 8580
  year: 1997
  ident: 10.1124/molpharm.122.000605_bib18
  article-title: Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.17-21-08580.1997
– volume: 94
  start-page: 1232
  year: 2018
  ident: 10.1124/molpharm.122.000605_bib39
  article-title: Intracellular binding site for a positive allosteric modulator of the dopamine D1 receptor
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.118.112649
– volume: 62
  start-page: 8711
  year: 2019
  ident: 10.1124/molpharm.122.000605_bib17
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.9b01234
– volume: 19
  start-page: 1365
  year: 2019
  ident: 10.1124/molpharm.122.000605_bib13
  article-title: Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026619666190712210903
– volume: 94
  start-page: 1197
  year: 2018
  ident: 10.1124/molpharm.122.000605_bib25
  article-title: Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.118.113175
– volume: 69
  start-page: 253
  year: 2014
  ident: 10.1124/molpharm.122.000605_bib10
  article-title: Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias
  publication-title: J Pharmacol Toxicol Methods
  doi: 10.1016/j.vascn.2014.01.002
– volume: 12
  start-page: 88
  year: 1965
  ident: 10.1124/molpharm.122.000605_bib27
  article-title: On the nature of allosteric transitions: a plausible model
  publication-title: J Mol Biol
  doi: 10.1016/S0022-2836(65)80285-6
– volume: 86
  start-page: 273
  year: 2019
  ident: 10.1124/molpharm.122.000605_bib35
  article-title: Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders
  publication-title: Adv Pharmacol
  doi: 10.1016/bs.apha.2019.06.001
– volume: 184
  start-page: 943
  year: 2021
  ident: 10.1124/molpharm.122.000605_bib41
  article-title: Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes
  publication-title: Cell
  doi: 10.1016/j.cell.2021.01.028
– volume: 12
  start-page: 205
  year: 2013
  ident: 10.1124/molpharm.122.000605_bib20
  article-title: Signalling bias in new drug discovery: detection, quantification and therapeutic impact
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd3954
– volume: 47
  start-page: 1
  year: 2007
  ident: 10.1124/molpharm.122.000605_bib26
  article-title: Allosteric modulation of G protein-coupled receptors
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev.pharmtox.47.120505.105159
– volume: 13
  start-page: 3186
  year: 2022
  ident: 10.1124/molpharm.122.000605_bib37
  article-title: Ligand recognition and biased agonism of the D1 dopamine receptor
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-30929-w
– volume: 559
  start-page: 45
  year: 2018
  ident: 10.1124/molpharm.122.000605_bib38
  article-title: Structural insights into G-protein-coupled receptor allostery
  publication-title: Nature
  doi: 10.1038/s41586-018-0259-z
– volume: 128
  start-page: 351
  year: 2018
  ident: 10.1124/molpharm.122.000605_bib7
  article-title: Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2017.10.032
– volume: 17
  start-page: 709
  year: 2022
  ident: 10.1124/molpharm.122.000605_bib16
  article-title: High-Throughput Screening for Extracellular Inhibitors of the FLT3 Receptor Tyrosine Kinase Reveals Chemically Diverse and Druggable Negative Allosteric Modulators
  publication-title: ACS Chem Biol
  doi: 10.1021/acschembio.2c00048
– volume: 360
  start-page: 117
  year: 2017
  ident: 10.1124/molpharm.122.000605_bib36
  article-title: An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.116.236372
– volume: 23
  start-page: 551
  year: 1983
  ident: 10.1124/molpharm.122.000605_bib34
  article-title: Modification of the binding properties of muscarinic receptors by gallamine
  publication-title: Mol Pharmacol
  doi: 10.1016/S0026-895X(25)14327-7
– volume: 63
  start-page: 182
  year: 2011
  ident: 10.1124/molpharm.122.000605_bib4
  article-title: The physiology, signaling, and pharmacology of dopamine receptors
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.110.002642
– volume: 38
  start-page: 939
  year: 1990
  ident: 10.1124/molpharm.122.000605_bib6
  article-title: Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes
  publication-title: Mol Pharmacol
  doi: 10.1016/S0026-895X(25)09591-4
– volume: 58
  start-page: 7076
  year: 2015
  ident: 10.1124/molpharm.122.000605_bib19
  article-title: An Aggregation Advisor for Ligand Discovery
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.5b01105
– volume: 597
  start-page: 571
  year: 2021
  ident: 10.1124/molpharm.122.000605_bib9
  article-title: Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia
  publication-title: Nature
  doi: 10.1038/s41586-021-03897-2
– volume: 354
  start-page: 340
  year: 2015
  ident: 10.1124/molpharm.122.000605_bib23
  article-title: Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.115.224071
– volume: 178
  start-page: S27
  issue: Suppl 1
  year: 2021
  ident: 10.1124/molpharm.122.000605_bib1
  article-title: THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors
  publication-title: Br J Pharmacol
– volume: 54
  start-page: 323
  year: 2002
  ident: 10.1124/molpharm.122.000605_bib8
  article-title: G protein-coupled receptor allosterism and complexing
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.54.2.323
– volume: 15
  start-page: 119
  year: 2010
  ident: 10.1124/molpharm.122.000605_bib21
  article-title: Ligand detection in the allosteric world
  publication-title: J Biomol Screen
  doi: 10.1177/1087057109357789
– ident: 10.1124/molpharm.122.000605_bib3
– volume: 287
  start-page: 651
  year: 1980
  ident: 10.1124/molpharm.122.000605_bib14
  article-title: Benzodiazepine recognition sites on GABA receptors
  publication-title: Nature
  doi: 10.1038/287651a0
– volume: 37
  start-page: 620
  year: 2016
  ident: 10.1124/molpharm.122.000605_bib12
  article-title: Cooperativity Has Empirical and Ultimate Levels of Explanation
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2016.06.001
– volume: 95
  start-page: 4040
  year: 1998
  ident: 10.1124/molpharm.122.000605_bib30
  article-title: Calcimimetics with potent and selective activity on the parathyroid calcium receptor
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.95.7.4040
– volume: 335
  start-page: 851
  year: 2012
  ident: 10.1124/molpharm.122.000605_bib15
  article-title: Crystal structure of a lipid G protein-coupled receptor
  publication-title: Science
  doi: 10.1126/science.1215904
– volume: 16
  start-page: 19
  year: 2017
  ident: 10.1124/molpharm.122.000605_bib32
  article-title: A comprehensive map of molecular drug targets
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.230
– volume: 31
  start-page: 593
  year: 2021
  ident: 10.1124/molpharm.122.000605_bib42
  article-title: Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor
  publication-title: Cell Res
  doi: 10.1038/s41422-021-00482-0
SSID ssj0014580
Score 2.4312174
Snippet An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 176
SubjectTerms Allosteric Regulation - physiology
Allosteric Site - physiology
Dopamine - metabolism
Humans
Receptors, Dopamine D1 - metabolism
Receptors, G-Protein-Coupled
Title Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor
URI https://dx.doi.org/10.1124/molpharm.122.000605
https://www.ncbi.nlm.nih.gov/pubmed/36804203
https://www.proquest.com/docview/2778972952
Volume 103
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFcadsICOhvawdjROn8ePYhbIbk0ilvlmO42iINInW5gF-Pcd2nATRTYOXqHLrJvX3-fSc43NB6INkifCk8sYKGDQOIgl7LqNkLP0ojWBvpcoGyF6Gs3lwuqCLweCsF7VUr5N9-WtjXsn_oApjgKvOkv0HZNsvhQF4DfjCFRCG670wvqhN9sdhWVbqxvWBAO0vBoDU3kGe6wwOHSr_7bt2r9pzAdCZK7HUyuWRp7VGVdmCw62OeuE65u5VXV3rnufdSodFvbrumDVTy8R6s0Gw_ujOmj6XebpqnTeizru3PikriU2cbpNm1rgfiN_FXzmJSbQ_opGYasOYE7MTv8cnvyc0PdsB5m9hTgJAYFnm5tfue8TUVg0ntPvvcuf1l1_5yfz8nMfHi_gBekjAZjD29Zez9kgpoKaNXvtsTQkquMnHDbe4TU25zQwx6kj8BD1u7Ah8YEnxFA1U8QztXlnAfo5w3OXVrUZ4F1_1oHyOTi1z8B_MwWWGDXNwxxxsmIPLAgNzsGMOPvKwY84LND85jg9n46arBuw_3ZhTgE3KGInADoetCNqvIFRpM4CxYOqDOI7SMDKptULSjCV-mgnQMzOl6CTTh9ov0VZRFuo1wjpQkU09KlSSBmEgRSjINFSSkUzRaSKHiLhF5LIpOa87n-TcmJ4k4G7lOaw8tys_RKN2UmUrrtz98dChwxul0SqDHGh098T3DksOIlWfk4lClfWKA3siBkYnJUP0yoLcPokPaxOQif_mHrO30aNux-ygrfVNrd6CCrtO3hlq_ga4nptn
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mutual+Cooperativity+of+Three+Allosteric+Sites+on+the+Dopamine+D1+Receptor&rft.jtitle=Molecular+pharmacology&rft.au=Wang%2C+Xushan&rft.au=Hembre%2C+Erik+J&rft.au=Goldsmith%2C+Paul+J&rft.au=Beck%2C+James+P&rft.date=2023-03-01&rft.issn=1521-0111&rft.eissn=1521-0111&rft.volume=103&rft.issue=3&rft.spage=176&rft_id=info:doi/10.1124%2Fmolpharm.122.000605&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon